Evaluation of Biological Activity of a Diazocine Derivative against Heart Failure Using an Ischemia-Reperfusion Injury Model

Drug Res (Stuttg). 2022 Sep;72(7):404-411. doi: 10.1055/a-1840-3199. Epub 2022 Jun 20.

Abstract

Background: There are studies, which suggest that some diazocine derivatives can exert effects on the cardiovascular system; however, these effects are not very clear.

Objective: The aim of this research was to evaluate the biological activity of a diazocine derivative against heart failure translated as area infarct.

Methods: Biological activity produced by diazocine derivatives against heart failure was determinate using an ischemia/reperfusion injury model. Besides, to characterize the molecular mechanism of effect exerted by diazocine derivative on left ventricular pressure (LVP) was determinate in an isolated rat heart model using nifedipine, PINAME TXA2, and quinalizarin as controls.

Results: The results showed that diazocine derivative decrease the infarct area and increase the LVP. However, the effect produced by diazocine derivative on LVP was inhibited in the presence of quinalizarin.

Conclusions: The results indicate that biological activity produced by diazocine derivative on left ventricular pressure is through protein CK2 activation; this phenomenon could be translated as a decrease in both infarct area and heart failure.

MeSH terms

  • Animals
  • Heart
  • Heart Failure* / drug therapy
  • Infarction
  • Myocardial Reperfusion Injury* / drug therapy
  • Nifedipine
  • Rats

Substances

  • Nifedipine